Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.42 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.42 |
| ▸ | ITGAV | P06756 | 1/20 | 0.42 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | CDC25A | P30304 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29864421 | 1.00 | KMT2A (0.50) | KMT2ARAB9ALMNAHTTMEN1 | |
| SCHEMBL5692314 | 0.85 | PARP1 (0.51) | KMT2ARAB9AMEN1ALDH1A1MAPK1 | |
| SCHEMBL7850241 | 0.84 | RAB9A (0.45) | KMT2ARAB9ALMNAHTTMEN1 | |
| SCHEMBL28852119 | 0.84 | ALDH1A1 (0.49) | KMT2ARAB9ALMNAHTTMEN1 | |
| SCHEMBL28470928 | 0.82 | ALDH1A1 (0.51) | KMT2ARAB9ALMNAHTTMEN1 | |
| SCHEMBL29577048 | 0.81 | ALDH1A1 (0.64) | KMT2ARAB9ALMNAHTTMEN1 | |
| SCHEMBL6090937 | 0.81 | ALDH1A1 (0.64) | KMT2ARAB9ALMNAHTTMEN1 | |
| SCHEMBL25400139 | 0.79 | ALDH1A1 (0.46) | KMT2ARAB9ALMNAHTTMEN1 | |
| SCHEMBL28326426 | 0.79 | ALDH1A1 (0.46) | KMT2ARAB9ALMNAHTTMEN1 | |
| SCHEMBL30536400 | 0.78 | KMT2A (0.48) | KMT2ARAB9ALMNAHTTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 296 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102165950-B | Bacteriostatic and bactericidal activity of phenylglycine derivative on escherichia coli | UNIV ZHEJIANG | 2014-02-26 | — | — | CN | claimed |
| US-8486370-B2 | Heterocyclic ligands for integrin imaging and therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-07-16 | — | — | US | claimed |
| CN-102144992-B | Bacteriostatic and bactericidal activity of phenylglycine derivatives to Staphylococcus aureus | UNIV ZHEJIANG | 2013-04-10 | — | — | CN | claimed |
| CN-102165950-A | Bacteriostatic and bactericidal activity of phenylglycine derivative on escherichia coli | UNIV ZHEJIANG | 2011-08-31 | — | — | CN | claimed |
| CN-102144992-A | Bacteriostatic and bactericidal activity of phenylglycine derivatives to Staphylococcus aureus | UNIV ZHEJIANG | 2011-08-10 | — | — | CN | claimed |
| US-20100310455-A1 | Heterocyclic Ligands for Integrin Imaging and Therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-12-09 | — | — | US | claimed |
| US-7576175-B2 | Amino acid terminated diphenylurea derivatives; display high binding affinity, specificity, and stability; use in treating cancer, inflammatory diseases, and autoimmune diseases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-08-18 | — | — | US | claimed |
| WO-2008031016-A2 | HETEROCYCLIC LIGANDS FOR INTEGRIN IMAGING AND THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-03-13 | — | — | WO | claimed |
| WO-2005122379-A9 | ALPHA-4 BETA-1 INTEGRIN LIGANDS FOR IMAGING AND THERAPY | UNIV CALIFORNIA (US) | 2006-03-09 | — | — | WO | claimed |
| US-20060019900-A1 | Alpha-4 beta-1 integrin ligands for imaging and therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-01-26 | — | — | US | claimed |
| WO-2005122379-A2 | ALPHA-4 BETA-1 INTEGRIN LIGANDS FOR IMAGING AND THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-12-22 | — | — | WO | claimed |
| US-4946761-A | POLYMER CONTAINING CARBOXYL END GROUPS | FUJI PHOTO FILM CO., LTD. (JP) | 1990-08-07 | — | — | US | claimed |
| US-20260083852-A1 | PROTEOGLYCAN MIMETICS FOR ENHANCED WOUND HEALING, ANGIOGENESIS, AND VASCULAR REPAIR | UNIV CALIFORNIA (US) | 2026-03-26 | — | — | US | disclosed |
| US-12485182-B2 | Proteoglycan mimetics for enhanced wound healing, angiogenesis, and vascular repair | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-12-02 | — | — | US | disclosed |
| US-20250302971-A1 | Therapeutic Nanomaterials | UNIV CONNECTICUT (US) | 2025-10-02 | — | — | US | disclosed |
| US-20250302762-A1 | NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF | UNIVERSITY OF CONNECTICUT (US) | 2025-10-02 | — | — | US | disclosed |
| US-5395733-A | Unsaturated polymer layer that can be decarboxylated on exposure to light and sensitizers | FUJI PHOTO FILM CO., LTD. (JP) | 1995-03-07 | — | — | US | disclosed |
| EP-0458485-A2 | Image forming layer | Fuji Photo Film Co., Ltd. (JP) | 1991-11-27 | — | — | EP | disclosed |
| US-4946761-A | POLYMER CONTAINING CARBOXYL END GROUPS | FUJI PHOTO FILM CO., LTD. (JP) | 1990-08-07 | — | — | US | disclosed |
| US-4405705-A | HYDROPHILIC | TOYO BOSEKI KABUSHIKI KAISHA T/A TOYOBA CO., LTD. (JP) | 1983-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250302971-A1 | Therapeutic Nanomaterials | TIE1, TEKT1, POLRMT | KMT2A 384/4885RAB9A 2256/4885LMNA 1574/4885 |
| US-20100310455-A1 | Heterocyclic Ligands for Integrin Imaging and Therapy | ITGA1, ITGAL, ITGA4 | KMT2A 2701/4885RAB9A 1592/4885LMNA 2248/4885 |
| US-20250302762-A1 | NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF | JAK2, JAK1, CHMP4B | KMT2A 1471/4885RAB9A 694/4885LMNA 1531/4885 |
| US-20060019900-A1 | Alpha-4 beta-1 integrin ligands for imaging and therapy | ITGA4, ITGB4, ITGA1 | KMT2A 3460/4885RAB9A 2130/4885LMNA 2391/4885 |
| US-12485182-B2 | Proteoglycan mimetics for enhanced wound healing, angiogenesis, and vascular repair | PDGFA, PDGFRB, TEK | KMT2A 4334/4885RAB9A 3778/4885LMNA 431/4885 |
| US-20260083852-A1 | PROTEOGLYCAN MIMETICS FOR ENHANCED WOUND HEALING, ANGIOGENESIS, AND VASCULAR REPAIR | PDGFA, DCLRE1A, PDGFRA | KMT2A 2690/4885RAB9A 2150/4885LMNA 401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.